No profile data available.
Syschem (India) Limited (SYSCHEM.BO) is a healthcare company in the drug manufacturing contractors industry, based in Chandigarh, India, with about 135 full-time employees.
It reported revenue of 3.86 billion INR for fiscal year 2025, up 65.5% from fiscal year 2024, and net income of 4.60 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 1.41 billion INR, up 82.0% from a year before. Its market capitalization was 2.02 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
Syschem (India) Limited engages in the production and sale of active pharmaceuticals ingredients (API), intermediates, and bulk drugs in India. Its APIs/intermediates include amoxycillin trihydrate, ampicillin trihydrate, cloxacillin sodium, dicloxacillin sodium, flucloxacillin sodium, cephalexin, and cefadroxil.
Syschem (India) reported 3.86 billion INR in revenue for fiscal year 2025, up 65.5% from 2.33 billion INR in fiscal year 2024. In Q3 2026 revenue was 1.41 billion INR.
2.02 billion INR as of October 9, 2026.
Listed companies of a similar size in the same industry (drug manufacturing contractors) include Gennex Laboratories Limited (GENNEX.BO), Brooks Laboratories Limited (BROOKS.NS), Coral Laboratories Limited (CORALAB.BO), Nectar Lifesciences Limited (NECLIFE.NS).